Borsellino et al. revealed that an anti-IL-6 antibody efficiently promotes a cytostatic effect on prostate cancer cells exposed to cisplatin in a sequential dependent manner (around 40% cytotoxicity) [44]. Here, IL6 is linked to prostate carcinoma.